SAR-MED SRL

Their core work

SAR-MED SRL is a private Italian company based in Iglesias, Sardinia, that has participated in the Graphene Flagship programme exclusively as a third party — meaning it provides services, facilities, or specialist support to one of the flagship's full beneficiaries rather than receiving EU funding directly. Based on the project portfolio (GrapheneCore2, GrapheneCore3, and 2D-EPL), the company's contribution is connected to graphene and 2D-materials research, likely in a technical support, infrastructure, or regional service role tied to a Sardinian research partner. Publicly available project data does not describe an independent R&D programme or commercial technology line of its own. Treat this profile as a partial picture: SAR-MED appears to be a supporting actor inside a very large flagship consortium rather than a driver of research.

What they specialise in

How they've shifted over time

Between 2018 and 2020 the single early project (GrapheneCore2) covered the broad Graphene Flagship portfolio — composites, energy, electronics, photonics, sensors, and biomedical applications. From 2020 onward, the two newer projects (GrapheneCore3 and 2D-EPL) narrow toward FET Flagship continuation and, crucially, the 2D materials pilot line. The trend is a move from generic flagship participation toward the industrial/pilot-production side of graphene research.

They are following the Graphene Flagship's own trajectory from exploratory research toward pilot-line and pre-industrial 2D materials production, which is where future Flagship-linked funding is concentrating.

How they like to work

SAR-MED does not lead projects and does not act as a direct beneficiary — all three participations are "third party" roles inside flagship-scale consortia. It sits inside very large networks (219 partner organisations across 21 countries) but always in a supporting capacity, likely linked to a single Sardinian research beneficiary. Partnering with them is effectively partnering with a supplier/associate of a Graphene Flagship member, not contracting an independent research team.

Through three Graphene Flagship projects, SAR-MED appears alongside 219 unique consortium partners across 21 countries. The exposure is pan-European, but the role is peripheral: it enters these networks through its link to a funded beneficiary rather than as an active partner in its own right.

What sets them apart

What distinguishes SAR-MED is its sustained presence as a third-party entity inside the Graphene Flagship — one of the EU's largest research initiatives — while based in Iglesias, Sardinia, a region with limited H2020 participation. For consortium builders this means a route into the Graphene Flagship ecosystem via a Sardinian channel. For businesses and scientists, however, there is little public evidence of independent research output or commercial technology, so the company is best seen as a local support node rather than a standalone expert.

Highlights from their portfolio

• 2D-EPL
  The Graphene Flagship's 2D Experimental Pilot Line — the programme's push toward industrial-scale production of 2D materials, and the most commercially relevant project in the portfolio.
• GrapheneCore3
  Third core phase of the Graphene Flagship (2020-2023), signalling continued involvement in Europe's flagship 2D materials programme.
• GrapheneCore2
  Broad-spectrum Graphene Flagship core project covering composites, energy, electronics, photonics, sensors, and biomedical applications — the entry point of SAR-MED into the flagship.